TOMI Environmental Solutions 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- TOMI Environmental Solutions Inc. reported third-quarter 2026 revenue of approximately $2.49 million, up approximately 24% from $2.01 million in Q3 2025 and 11% from $2.25 million in Q2 2026.
- Revenue for the first 9 months of 2026 increased 38% to approximately $6.39 million, including 61% growth in product revenue.
- Product sales increased approximately 30% year over year to approximately $2.08 million, while US revenue increased 50% to approximately $1.92 million.
- Gross profit increased 19% year over year to approximately $1.47 million, and operating expenses declined 7% to approximately $1.44 million from approximately $1.55 million.
- TOMI generated approximately $30,000 of positive operating income, its first positive quarterly operating result since Q3 2024, compared with operating losses of approximately $321,000 in Q3 2025 and $244,000 in Q2 2026.
- The company reported working capital of approximately $1.95 million, up from $1.02 million at the end of 2025, and sales order backlog of approximately $2.5 million at September 30th, which had since increased to approximately $2.8 million.
- Management said the review of accounting treatment for convertible notes, including the conversion of $2.5 million of notes during the 3rd quarter, is incomplete; related results remain subject to change until the company files its quarterly report on Form 10-Q for the period ended September 30th, 2026.
- Management expects any impact from the accounting review to be non-cash and said it does not expect the review to affect revenue, gross profit, operating expense, or income from operations.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
It's now my pleasure to turn the floor over to your host, John Nesbett at IMS Investor Relations.
The floor is yours. Thank you for joining us today for the TOMI Environmental Solutions Investor Update Conference Call.
On today's call are TOMI's Chief Executive Officer and Chairman, Dr. Halden Shane, Chief Operating Officer, EJ Shane, and our Chief Financial Officer, Niroshan Srirathan. A telephone replay of today's call will be available through November 19, 2026, the details of which are included in the company's press release. A webcast replay will also be available at TOMI's website, www.steramist.com. Certain written and oral statements made by management of TOMI may constitute forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements should be evaluated in light of important risk factors that could cause actual results to differ materially from our anticipated results. The information provided in this conference call is based upon the facts and circumstances known at this time.
Please refer to our filings with the SEC for a discussion of these risk factors. The company undertakes no obligation to update these forward-looking statements after the date of this call. I will now turn the call over to TOMI's Chief Executive Officer and Chairman of the Board, Dr. Halden Shane.
Please go ahead. Thank you, John, and thank you all for joining us today.
What a day it is. We delivered another consecutive quarter of sequential revenue growth, extending the upward trend we have maintained throughout 2026. Revenue increased approximately 36% from the first quarter to the second, and a further 11% from the second quarter to the third. Third quarter revenue now stands approximately 51% above the first quarter. This is a steady sequential progress built across the year, not a one-quarter result. We generated positive operating income for the first time since the third quarter of 2024. The strategic initiatives we have implemented are working. Revenue for the third quarter of 2026 was approximately $2.49 million. That's up about 24% from the $2.01 million in the third quarter of 2025. As stated, 11% from the $2.25 million last quarter.
Our sales order backlog is approximately $2.5 million as of September 30th, and has since increased to approximately $2.8 million. The company expects shareholder equity at September 30th, 2026, to be in a range of $3 million-$4 million. The company and its independent registered public accounting firm have not yet completed the review of the accounting treatment for the company's convertible notes, including the conversion of $2.5 million of notes during the third quarter. Accordingly, we will not review the financial results that may be affected by that review, including any gain or loss associated with the conversion, net loss, net loss per share, and the related liability and stockholders' equity balances.
Based on the information currently available, we expect any impact from this accounting treatment to be a non-cash, and the company does not expect the review to affect the revenue, gross profit, operating expense, or income from operation figures. However, all the results remain subject to change until the company files its quarterly report on Form 10-Q for the period ended September 30th, 2026. BIT Solution demand is showing steady increase as well this year. Delivered BIT Solution sales year to date, together with orders that remain open, have already surpassed BIT Solution sales for all of last year. As we reach that mark with two months still ahead of us, service continues to trend higher. The sharpest break from recent years is mobile equipment. Mobile equipment year to date, together with open orders, is above last year's full total by almost 107%.
For the past two years, we have said that continuous growth depends on each of our departments rising together, not one or two of our offerings carrying the year. We expect 2026 to end on that basis, providing us good visibility into near-term revenue. We are continuing our razor-razor blade model, and the applicator is now a core part of it. The applicator is the component that enables iHP, whether it's paired with a mobile system or installed in a permanent or semi-permanent configuration. We began emphasizing this strategy less than two years ago as an extension of our consumable-driven model. It, of course, has a longer replacement cycle than BIT Solution, but a much shorter sales cycle and full capital equipment. So, it generates revenue and margin now while it supports recurring BIT Solution demand down the road.
Our current sales opportunity pipeline has projected value of approximately $35 million. It includes opportunities at every stage of the sales process, from proposals to negotiations to purchasing, and it's supported by continued growth in Integrated System opportunities involving our SteraMist Integrated System platform, or SIS, Hybrid, and Custom Engineered System, or CES, configurations. I want to be clear that these represent potential future revenue. They're not committed orders yet or guarantees of future performance. We remain focused on our goal of $12 million in sales for 2026. Our sales team is small, but is dedicated and is working hard to reach that benchmark. On the cost side, our disciplined overhead management continues to pay off. Operating expenses for the quarter were approximately $1.44 million, down 7% from a year ago, led by savings in general and administrative costs.
Working capital increased to approximately $1.95 million, up from $1.02 million at the end of 2025. Let me update you on several last quarter items. First, the nearly $1 million project we introduced last quarter, adding applicators into proprietary machine lines at a major multinational healthcare manufacturer, is underway. That customer is now expanding into additional facilities, taking advantage of our recently received European Union regulatory acceptances. TOMI continues to expand its presence in the defense sector. Following approvals from defense contractors in Korea and defense agencies in Canada, we have developed a very detailed strategic plan for these accounts and have provided one of the two agencies with systems that are ready to be deployed. TOMI iHP Corporate Service continues to grow. We now have contracted decontamination service engagements with customers, including Integra Pharma, Catalent, Cleveland Clinic, and LFB USA.
Our team is providing on-site support about four times a month, including at the Centers for Disease Control and Prevention in Atlanta. A production change at one large customer that no longer requires decontamination services has weighed on our year-over-year comparison in service revenue, but we have partially offset that impact, and we are actively expanding our service deployment business, including pathways to deliver corporate services directly to the end users internationally. In the third quarter, we continued to add partners. SteraMist iHP activity across the Americas increased in life sciences, food safety, and healthcare. We brought on additional partners in Mexico and a new one in Argentina, while we completed further business in India and the European Union. We continue to work with our legacy partner in Mexico on a previously announced cheese factory.
That work is still generating strong data on extending the shelf life of cheese, and we have expanded into other food groups and applications with them. Older customers, including Thermo Fisher, continue to expand capital equipment purchases. We also expanded our relationship with a leading global eye health company. This customer onboarded in 2025 at two locations, placed an additional equipment order late into quarter three. Combined revenue for the two sites is approximately $750,000, and they have a recurring BIT Solution agreement with TOMI. Further orders at both facilities, additional equipment systems, and a Custom Engineered System for integrated automated decontamination are still prospective. We anticipate that some or all of them could be received before year-end in a range of approximately $960,000-$1.7 million. We are putting resources behind the pipeline and behind customer requirements across our product and service line.
We expect that focus to hold through the close of the year, and we look forward to reporting how 2026 finishes. I am going to now turn the call over to our Chief Financial Officer, Niro Srirathan, for a review of TOMI's third quarter financial results.
Thank you, Dr. Shane. Q3 marked an important financial inflection point for TOMI. Revenue increased 24% year-over-year and 11% sequentially to approximately $2.49 million, compared with approximately $2.01 million in Q3 2025 and $2.25 million in Q2 2026. We generated approximately $30,000 of positive operating income, our first positive quarterly operating result since Q3 2024. Revenue growth was led by product sales, which increased approximately 30% year-over-year to approximately $2.08 million, compared with approximately $1.6 million in Q3 2025. U.S. revenue increased 50% to approximately $1.92 million. For the first nine months of 2026, total revenue increased 38% to approximately $6.39 million, including 61% growth in product revenue. Gross profit increased 19% year-over-year to approximately $1.47 million, compared with approximately $1.23 million in Q3 2025.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
8 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
